Hire an Advanced Robo-Advisor to Trade BCR on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
What is Robo investing?
Smart Auto-Trading is an advanced robo-advisor designed to provides investors with a a state of the art automated trading tool to trade the S&P 500. Its robo is designed to screens, monitors and auto-trades elite stocks like C.R. BARD, INC. (BCR) using artificial intelligence, social media and market data to augments your potential as an investor.
What is it good at?
If you are interested in systematic, active investing, Smart Auto-Trading can be a great alternative to passive investing funds. Smart Auto-Trading uses artificial intelligence concepts to screen, monitor and auto-trade stocks. Used in a tax-deferred account such as an IRA, SIMPLE IRA, Rollover IRA, Keogh, 529 College Plan or UGMA it auto-trades systematically using your carefully defined strategy. Using Smart Auto-Trading is like having a professional trader working for you. You turn it on and it just works.
Smart Auto-Trading actively trades the S&P 500 day-in and day-out in your account while you attend more important life events. Because of the systematic nature of Smart Auto-Trading, your account has the potential to grow at a higher rate than if you were to use a passive investment vehicle such as an index fund or a mutual fund. Systematic active trading using artificial intelligence holds the potential to grow the account faster.
Using Smart Auto-Trading is Easy
To connect Smart Auto-Trading to your account you will need to open an account with Ally Invest, one of the most trusted broker/dealer in the United States. Ally Invest is the brokerage firm Stock Circles uses to auto-trade because Ally Invest offers a very competitive price per trade.
To open an account, please go to Ally Invest's account opening page is available at: https://invest.ally.com/ola/
Once the account is open, you are ready to transfer your money into the newly opened account. To do so, you will need to send a copy of your 401K or other account statement to Ally Invest as well as transfer instructions to firstname.lastname@example.org. Once they receive your instructions, a Customer Support specialist will help you complete the transfer.
After a few business days, the account will be funded and you will be ready to auto-trade using Smart Auto-Trading.
While this is in progress, you might want to test your strategy in simulation mode free of charge at stockcircles.com. Doing so will help you get comfortable with the product's benefits.
There are clear benefits associated with using a robo-advisor such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Smart Auto-Trading is one of the first robo-advisor to take advantage of Government grade listening technology, artificial intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Advisors like other investment methods rely on favorable market conditions to provide positive outcomes.
C.R. BARD, INC. (BCR) News
C.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $989.81 Million
Brokerages expect C.R. Bard, Inc. (NYSE:BCR) to announce $989.81 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for C.R. Bard’s earnings. The lowest sales estimate is $986.40 million and the highest is $997.00 million. C.R. Bard reported sales of $941.90 million in the same quarter last year, which indicates a positive year-over-year growth rate of 5.1%. The business is expected to report its next earnings results on Tuesday, October 24th.
On average, analysts expect that C.R. Bard will report full-year sales of $989.81 million for the current financial year, with estimates ranging from $3.92 billion to $3.95 billion. For the next year, analysts forecast that the company will post sales of $4.15 billion per share, with estimates ranging from $4.09 billion to $4.23 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover C.R. Bard.
C.R. Bard (NYSE:BCR) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The company had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.54 earnings per share.
A number of brokerages have weighed in on BCR. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $292.00.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.80% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of BCR. UBS Asset Management Americas Inc. boosted its stake in C.R. Bard by 10.2% in the first quarter. UBS Asset Management Americas Inc. now owns 294,759 shares of the medical instruments supplier’s stock worth $73,259,000 after purchasing an additional 27,308 shares in the last quarter. Airain ltd boosted its stake in C.R. Bard by 302.6% in the first quarter. Airain ltd now owns 11,957 shares of the medical instruments supplier’s stock worth $2,972,000 after purchasing an additional 8,987 shares in the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in C.R. Bard by 72.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 14,559 shares of the medical instruments supplier’s stock worth $3,618,000 after purchasing an additional 6,116 shares in the last quarter. First National Trust Co. acquired a new position in C.R. Bard in the first quarter worth $220,000. Finally, Baird Financial Group Inc. boosted its stake in C.R. Bard by 14.5% in the first quarter. Baird Financial Group Inc. now owns 32,027 shares of the medical instruments supplier’s stock worth $7,960,000 after purchasing an additional 4,049 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.
Shares of C.R. Bard (NYSE:BCR) opened at 318.75 on Thursday. The company has a market capitalization of $23.16 billion, a PE ratio of 41.85 and a beta of 0.60. The firm has a 50-day moving average price of $320.07 and a 200-day moving average price of $299.22. C.R. Bard has a 1-year low of $203.63 and a 1-year high of $324.58.Get Started today! - Risk Free